Patents Examined by Robert S Cabral
  • Patent number: 12005125
    Abstract: A nanocomposition for use in treating cardiac, oncologic, bariatric, or dermatologic indications, conditions and diseases condition using phthalocyanine dye, such as IR700. A nanocomposition having IR700, an 8PEG nanoparticle and a RGD, or iRGD targeting agent. Administering a product comprising IR700 to a patient, whereby the IR700 is delivered to the target tissue, and found in only target tissue; and administering light to activate the IR700, thereby producing an ROS.
    Type: Grant
    Filed: April 12, 2021
    Date of Patent: June 11, 2024
    Assignee: Mi2 Holdings LLC
    Inventors: Andrew Hopkins, Thomas Hopkins
  • Patent number: 11998603
    Abstract: Compositions comprising a fluorescein component and benoxinate component and the corresponding uses of these compositions are described herein. These compositions have improved storage life and the fluorescein component and/or benoxinate component minimally degrade after 12 to 18 months of storage.
    Type: Grant
    Filed: September 26, 2022
    Date of Patent: June 4, 2024
    Inventors: Patrick H. Witham, Sailaja Machiraju
  • Patent number: 11998638
    Abstract: The invention relates to a process for preparing PCL-comprising microparticles, to microparticles obtainable by said process, to gel hence obtained and to several uses of the gel such as for the preparation of a medicament for treating a skin abnormality or disfigurement, and/or for controlling bladder function and/or controlling gastric reflux and/or for treating erectile dysfunction and/or for treating vocal cords. The gel may also be used for cosmetic applications.
    Type: Grant
    Filed: December 14, 2021
    Date of Patent: June 4, 2024
    Assignee: AQTIS I.P B.V.
    Inventors: Henderikus Super, Paul Willem Mijnen, Pieter Gerard Zijlstra, Dirk Wybe Grijpma
  • Patent number: 11998642
    Abstract: The invention provides a droplet encapsulate comprising: a drop of a hydrophobic medium; a peripheral layer of non-polymeric amphipathic molecules around the surface of the drop; and an aqueous droplet within the peripheral layer, the aqueous droplet comprising: (a) an aqueous medium and (b) an outer layer of non-polymeric amphipathic molecules around the surface of the aqueous medium. The invention also provides processes for preparing the droplet encapsulates. Various uses of the droplet encapsulates are also described, including their use as drug delivery vehicles, in synthetic biology, and in the study of membrane proteins.
    Type: Grant
    Filed: June 29, 2022
    Date of Patent: June 4, 2024
    Assignee: Oxford University Innovation Limited
    Inventors: John Hagan Pryce Bayley, Andrew Heron, Gabriel Villar
  • Patent number: 11998658
    Abstract: Injectable macroporous hydrogels, and methods of producing same, are described. The injectable macroporous hydrogels may be formed by mixing gelatin microgels with an enzyme. In at least some embodiments, the enzyme may be transglutaminase, and more specifically microbial transglutaminase (mTG).
    Type: Grant
    Filed: February 10, 2020
    Date of Patent: June 4, 2024
    Assignee: University of New Hampshire
    Inventor: Kyung Jae Jeong
  • Patent number: 11981714
    Abstract: The present invention pertains to the nanoencapsulation of siRNA and other biologics in phospholipid nanosomes for the improved delivery of siRNA and other biologics to targeted diseased human or animal organs and human or animal cells and apparatus and methods for making the same. In embodiments of the present invention, novel siRNAs were designed to down regulate CCR5 and CD4, based on an analysis of all known alternative transcripts for each gene from both human and monkey (Macaca mulatta) genomes. Embodiments of the present invention feature supercritical, critical and near critical fluids. Embodiments of the present invention also pertain to down regulation of CXCR4 receptor and targeting of nanosomes containing specific siRNA sequences to cells expressing those receptors on the cell surface by coating them with specific ligands. These include ligands for the receptors CCR5, CD4 and CXCR4.
    Type: Grant
    Filed: November 12, 2020
    Date of Patent: May 14, 2024
    Inventors: Trevor Percival Castor, Vasudevacharya Jayarama, James A McSwiggen
  • Patent number: 11981928
    Abstract: Described herein are human transgenic beta cells expressing fugetactic levels of CXCL12 to a subject in need thereof. Also described herein are beta cells comprising a transgene comprising a nucleic acid sequence encoding CXCL12.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: May 14, 2024
    Assignee: SDF BIOPHARMA INC.
    Inventors: Gerald F. Swiss, David Kiewlich
  • Patent number: 11981757
    Abstract: A high molecular weight polyethylene polymer is formulated so that the polymer is capable of being injection molded. The polyethylene polymer has a Viscosity Number of greater than about 400 ml/g and has a melt flow rate of greater than about 0.9 g/10 min. The polyethylene polymer is of high purity and is particularly well suited for producing medical products.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: May 14, 2024
    Inventors: Christina Schmid, Rainer Walkenhorst
  • Patent number: 11975072
    Abstract: The invention relates to a compound of formula (I) and to the pharmaceutically acceptable salts thereof. The invention also relates to the use of said compound of formula (I) in the treatment of cancer, particularly by photodynamic therapy.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: May 7, 2024
    Inventors: Henri Azais, Pierre Collinet, Nadira Delhem-Fellahi, Olivier Morales, Serge Mordon, Céline Frochot, Régis Vanderesse, Aurélie Stallivieri
  • Patent number: 11969506
    Abstract: The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include an ionizable lipid, a phospholipid, a first sterol or a tocopherol, and optionally a second sterol different from the first sterol. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: April 30, 2024
    Assignees: ModernaTX, Inc., Oregon State University
    Inventors: Siddharth Patel, Emily Robinson, Anna Brown, Orn Almarsson, Kerry E. Benenato, Staci Sabnis, Gaurav Sahay, Ashwani Kumar Narayana
  • Patent number: 11951232
    Abstract: One aspect of the present disclosure can include a biocompatible tissue graft. The graft can include an extracellular matrix (ECM) patch or strip and at least one fiber stitched into the ECM patch or strip in a peripheral reinforcement pattern. The at least one fiber can have opposing terminal ends. The at least one fiber can mitigate tearing and/or improve fixation retention of the ECM patch or strip. The at least one fiber can comprise a plurality of interconnected stitches. The opposing terminal ends of the at least one fiber can be stitched together to form a continuous stitching construction.
    Type: Grant
    Filed: June 17, 2020
    Date of Patent: April 9, 2024
    Inventors: Kathleen Derwin, Amit Aurora, Joseph P. Iannotti, Jesse A. McCarron
  • Patent number: 11952439
    Abstract: The invention relates to a surface gradient cross-linked method of a ultra-high molecular weight polyethylene and the application thereof. The surface gradient crosslinked method of ultrahigh molecular weight polyethylene includes a n ultra-high molecular weight polyethylene surface photoinitiator diffusion step and an ultraviolet light irradiation crosslinking step. In this method, the photoinitiator is diffused deeply into the surface of ultra-high molecular weight polyethylene, the body material shows a gradient cross-linking from the surface to the inside after ultraviolet irradiation so that the whole bulk has a high toughness and the surface there of has a high wear resistance.
    Type: Grant
    Filed: June 25, 2020
    Date of Patent: April 9, 2024
    Assignees: b-ONE Medical (Suzhou) Co., Ltd., b-ONE Medical Biotech Corporation, b-ONE Orth, Corp
    Inventor: Zongtao Zhang
  • Patent number: 11944706
    Abstract: The present invention provides a hybrid biocompatible carrier (hybridosome) which comprises structural and bioactive elements originating from at least one biocompatible delivery module (BDM) and at least one engineered drug encapsulation module (EDEM) comprising at least one tunable fusogenic moiety. The invention further provides pharmaceutical compositions comprising said hybridosomes, processes for their manufacture, as well as pharmaceutical uses and pharmaceutical methods based thereon.
    Type: Grant
    Filed: September 12, 2022
    Date of Patent: April 2, 2024
    Assignee: Anjarium Biosciences AG
    Inventor: Joel de Beer
  • Patent number: 11913884
    Abstract: Disclosed herein are photoactivable fluorophores comprising one or more thiocarbonyl groups as well as conjugates and compositions thereof. The present disclosure also provides methods of preparing photoactivatable fluorophores as well as methods of imaging using the photoactivatable fluorophores, conjugates, and compositions of the present disclosure.
    Type: Grant
    Filed: February 24, 2020
    Date of Patent: February 27, 2024
    Assignee: William Marsh Rice University
    Inventors: Han Xiao, Juan Tang
  • Patent number: 11905246
    Abstract: A molecular building block composition can include a metal ion component; and a ligand component including a core including at least one functional group associated with the metal ion component and the core.
    Type: Grant
    Filed: February 9, 2021
    Date of Patent: February 20, 2024
    Assignee: King Abdullah University of Science & Technology
    Inventors: Mohamed Eddaoudi, Dongxu Xue, Ryan Luebke, Vincent Guillerm, Abdul Malik Puthan Peedikakkal, Karim Adil, Lukasz Weselinski
  • Patent number: 11904024
    Abstract: The present invention relates to an eye-drop composition comprising 2-amino-9-[[(1S,2R)-1,2-bis(hydroxymethyl)cyclopropyl]methyl]-1,9-dihydro-6H-Purin-6-one, and the use thereof for the diagnosis and treatment of herpetic eye infections in companion animals.
    Type: Grant
    Filed: March 18, 2021
    Date of Patent: February 20, 2024
    Assignee: Aratana Therapeutics, Inc.
    Inventors: Nesya Goris, Johan Neyts, Erwin Blomsma, Stefaan Wera, Ainola Billiet, Joeri Auwerx, Veerle Debeurme, Maryline Roe, Pascal Puig
  • Patent number: 11896037
    Abstract: The present invention relates to compositions and methods for masking the taste of an agent. In certain aspects, the invention comprises a microsphere and at least one sweetener therein. In another aspect, the invention comprises an edible material comprising at least one microsphere comprising an agent and at least one microsphere comprising a sweetener.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: February 13, 2024
    Assignee: Temple University-Of The Commonwealth System of Higher Education
    Inventors: Gregory S. Smutzer, Kevin Lee, Dhruti Patel
  • Patent number: 11890351
    Abstract: Novel biomolecular conjugates containing non-natural aromatic chemical moieties covalently coupled to a diazonium compound and methods of their use are disclosed.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: February 6, 2024
    Assignee: Trustees of Boston College
    Inventors: Abhishek Chatterjee, Partha Sarathi Addy
  • Patent number: 11883540
    Abstract: The present application relates to a vehicle whose shell material is modified with at least one additional secondary phase that acts as a cork. In the presence of an energy source (preferably ultrasound), the corks embedded in the shell are either removed from the shell to create permanent pores or perturbed within the shell to create transient pores that can control transport in or out of the vehicle.
    Type: Grant
    Filed: May 14, 2021
    Date of Patent: January 30, 2024
    Assignee: McMaster University
    Inventors: Todd Hoare, Jonathan Dorogin, David Koff, Andrew Singh
  • Patent number: 11878090
    Abstract: This invention provides solid substrates for promoting cell or tissue growth or restored function, which solid substrate is characterized by a specific fluid uptake capacity value of at least 75%, which specific fluid uptake capacity value is determined by establishing a spontaneous fluid uptake value divided by a total fluid uptake value. This invention also provides solid substrates for promoting cell or tissue growth or restored function, which solid substrate is characterized by having a contact angle value of less than 60 degrees, when in contact with a fluid. This invention also provides solid substrates for promoting cell or tissue growth or restored function, which said substrate is characterized by a substantial surface roughness (Ra) as measured by scanning electron microscopy or atomic force microscopy. The invention also provides for processes for selection of an optimized coral-based solid substrate for promoting cell or tissue growth or restored function and applications of the same.
    Type: Grant
    Filed: September 10, 2021
    Date of Patent: January 23, 2024
    Assignee: CARTIHEAL (2009) LTD.
    Inventor: Nir Altschuler